JAK1 and acute lymphoblastic leukemia: Ruxolitinib is a JAK1/2 inhibitor that has shown efficacy as a single agent in xenograft models of ETP T-ALL[91] and Ph-like ALL[92], and has been shown to sensitize ALL cells to glucocorticoids in vitro[84,85,89].